UK

Brexit's Disruptive Impact On U.K. And European Prescription Drug Market
Brexit's Disruptive Impact On U.K. And European Prescription Drug Market
Forbes
Brexit
UK
Europe
Flag link:
As negotiations with England labor on, Scotland rejects routine use of Vertex's cystic fibrosis drugs
As negotiations with England labor on, Scotland rejects routine use of Vertex's cystic fibrosis drugs
Endpoints
Vertex Pharmaceuticals
UK
Scotland
cystic fibrosis
Flag link:
Science sector lauds UK’s visa scheme, but repeats no-deal Brexit warning
Science sector lauds UK’s visa scheme, but repeats no-deal Brexit warning
Pharmaforum
UK
Brexit
visas
Flag link:
Bayer teams up with AI firm Sensyne Health to mine NHS data for its heart disease pipeline
Bayer teams up with AI firm Sensyne Health to mine NHS data for its heart disease pipeline
Fierce Biotech
Bayer
UK
Sensyne Health
artificial intelligence
cardiovascular disease
Flag link:
AstraZeneca to shell out £12M in severance dispute with workers at former England plant
AstraZeneca to shell out £12M in severance dispute with workers at former England plant
Fierce Pharma
AstraZeneca
UK
Flag link:
NICE recommends funding for psoriasis and type 1 diabetes drugs
NICE recommends funding for psoriasis and type 1 diabetes drugs
Pharmaforum
NICE
UK
NHS
AbbVie
Skyrizi
AstraZeneca
Farxiga
Flag link:
U.K. launches subscription model to pay for antibiotics
U.K. launches subscription model to pay for antibiotics
BioCentury
UK
antibiotics
subscription model
Flag link:
How This Startup Is Applying Machine Learning To Disease Diagnosis
How This Startup Is Applying Machine Learning To Disease Diagnosis
Forbes
Feebris
UK
diagnostics
respiratory disease
artificial intelligence
machine learning
Flag link:
Investors fret as new regulatory probes spur fresh delays to Roche's $4.3B Spark buyout
Investors fret as new regulatory probes spur fresh delays to Roche's $4.3B Spark buyout
Endpoints
Spark Therapeutics
Roche
FTC
UK
M&A
Flag link:
BIO Roundup: Agenus, FDA, Merck’s Frazier and Much More
BIO Roundup: Agenus, FDA, Merck’s Frazier and Much More
BioSpace
Agenus
Jamie Dimon
BIO 2019
RWE
FDA
immuno-oncology
Merck
Ken Frazier
UK
Flag link:
Orkambi parents start ‘buyers club’ to import generic version of CF drug
Orkambi parents start ‘buyers club’ to import generic version of CF drug
Pharmaforum
cystic fibrosis
patients
UK
Orkambi
Vertex Pharmaceuticals
Flag link:
BI chief “regrets” Brexit, but continues to invest in UK
BI chief “regrets” Brexit, but continues to invest in UK
Pharmaforum
UK
Brexit
Boehringer Ingelheim
Flag link:
UK R&D Roundup: Pharma gets in on the biotech boom
UK R&D Roundup: Pharma gets in on the biotech boom
Pharmaforum
UK
Brexit
biotech
R&D
Flag link:
AstraZeneca's Imfinzi gets a lift in lung cancer from England's cost watchdogs
AstraZeneca's Imfinzi gets a lift in lung cancer from England's cost watchdogs
Fierce Pharma
AstraZeneca
Imfinzi
lung cancer
NICE
UK
Flag link:
Vertex destroys nearly 8,000 Orkambi packs amid U.K. pricing standoff
Vertex destroys nearly 8,000 Orkambi packs amid U.K. pricing standoff
Fierce Pharma
Vertex Pharmaceuticals
Orkambi
drug pricing
UK
Flag link:
As Brexit row become increasingly anarchic, is UK’s reputation with pharma suffering?
As Brexit row become increasingly anarchic, is UK’s reputation with pharma suffering?
Pharmaforum
Brexit
UK
Europe
Flag link:
Sanofi may airlift medicines into UK after Brexit
Sanofi may airlift medicines into UK after Brexit
Pharmaforum
Sanofi
UK
Europe
Brexit
vaccines
flu vaccines
Flag link:
Brexit delay offers biopharma more time to prepare for a no-deal
Brexit delay offers biopharma more time to prepare for a no-deal
BioCentury
Europe
UK
Brexit
drug shortages
Flag link:
UK biotech industry booms on record investment – analysis
UK biotech industry booms on record investment – analysis
Pharmaforum
UK
biotech
R&D
Flag link:
UK gets early access to Roche’s breast cancer immunotherapy
UK gets early access to Roche’s breast cancer immunotherapy
Pharmaforum
Roche
Tecentriq
Celgene
Abraxane
UK
triple-negative breast cancer
Flag link:

Pages